We are a skilled team of pharma and R&D professionals with extensive big pharma and biotech experience in drug discovery and development for several products now launched on the global market.
Chairman of the board
Born 1965. B.Sci in chemistry from Stockholm University, a PhD in experimental neurology from Uppsala University and has been a postdoctoral fellow at the University of Southern California (USC), School of Pharmacy. Started as Chairman of Oblique Therapeutics AB 2023. Board member: Board director of CombiGene Ab (publ), Emplicure Ab (publ), Pergamum AB and Pergasus AB.
Main work experience: Jonas has worked for over 25 years in the Life Science sector. He is an associate professor of pharmacology at Uppsala University. He has trained in strategic planning and business leadership. Previously, he has held management roles in companies in Sweden, Switzerland and USA. Most recently, Jonas was CEO of the Swiss biotechnology company BOWS Pharmaceuticals SA; before that he was active in companies such as Pharmacia, Biovitrum, Sequenom and Invitrogen. He is currently the CEO of Promore Pharma Ab.
Member of the board
Born 1959. Master of Science in Chemical Engineering, Chalmers University of Technology, Gothenburg.
Board member of Oblique Therapeutics Ab: Member since 2021.
Chairman of the Board: MDA Management Ab, Sahlgrenska Science Park Ab, Saminvest Ab, Occlutech Ab and the Royal Swedish Academy of Engineering Sciences (IVA West).
Board member: Linc Ab, Promore Pharma Ab.
Member: Dental and Pharmaceutical Benefits Agency (TLV) transparency council.
Shareholding in Oblique Therapeutics Ab: no shares.
Main work experience: Marianne was previously CEO of Kronans Droghandel Ab, Sjätte AP-fonden and Global Health Partner Ab and Deputy CEO of Apoteket Ab
Member of the board
Born 1971. Studied Economics and Law at the School of Business and Economics and at the School of Public Administration, University of Gothenburg.
Board member of Oblique Therapeutics: Chairman of the Board from 2016 -2021 and from 2021 member of the board
Board member: Promore Pharma Ab, S.P. HMSO Göteborg Ab, Inorbit Therapeutics Ab and Deputy Chairman in Alligator Bioscience Ab
Shareholding in Oblique Therapeutics Ab: no shares
Main work experience: Hans-Peter has +20 years of experience in Investment Banking, Private Banking and Asset Management. Hans-Peter has held senior positions at Swedbank Markets, UBS AG, Danske bank and Söderberg & Partners. Hans-Peter has been involved as a board member in Swedish and international companies in Finance and Life Science such as Ancoria Insurance Public Ltd and Irlab Therapeutics Ab
Member of the board
Born 1973. Professor of Cellular and Molecular Pain Physiology, Karolinska Institutet, Ph.D in Molecular Pathology, UC San Diego, M.Sc in Pharmaceutical Biosciences, Uppsala University.
Board member of Oblique Therapeutics AB: member since 2021.
Member: Scandinavian Association for the Study of Pain, Stiftelsen Vectis.
Shareholding in Oblique Therapeutics Ab: no shares.
Main work experience: Professor of cellular and molecular pain physiology, research group leader and management team member at the Department of Physiology and Pharmacology, Karolinska Institutet. Member and chairman of the Swedish Young Academy. Scientific advisor and speaker for Cellectricon, Eli Lilly, BMS, Pfizer and others
Member of the board
Born 1971. PhD in biomedical research from University of Copenhagen and did his post-doctoral training at Institute Pasteur in Paris. Started as board member of Oblique Therapeutics AB 2023. Chairman of the Board at Atlas Antibodies AB and Atlas Incentives AB.
Main work experience: Søren has more than 20 years of international experience from operational and strategic leadership positions in global pharma and the biotech industry including executive roles at Novo Nordisk, Symphogen and Macrophage Pharma. He has negotiated and operationalized numerous licensing, collaboration and co-development agreements. He is currently the CEO of Alligator Bioscience. Independent in relation to the Company and its management.
Chief Executive Officer (CEO)
Christer Nordstedt M.D. Ph.D. has over 25 years of experience in various executive positions in the international pharmaceutical industry.
Christer Nordstedt has abroad and extensive international experience within the pharmaceutical industry from operational and strategic positions at management level in companies like Vivesto, Teva Pharmaceuticals, Orion Corporation, Eli Lilly, Roche, AstraZeneca among others. During his career, Christer has been responsible for large global research projects and leadership in both management, executive, and board roles.
Christer’s latest position was interim Chief Executive Officer (CEO) for Vivesto, a pharmaceutical manufacturing company, Uppsala, Sweden. Christer holds a MD and PhD degrees in Pharmacology and Biochemistry from Karolinska Institutet, Sweden. His insights include discovery and clinical development work in neurodegeneration, pain, oncology, and psychiatry.
Chief Scientific Officer (CSO)
Dr. Olof Larsson is a pharmacologist with core expertise in pain, neuroscience, and in particular ion channels with excess of 30 years of experience from executive positions in several international big pharma, biotech and start-ups. These include CSO in Pain & Migraine at Eli Lilly, and Scientific site leader Neuroscience, Eli Lilly, US. He has over 90 publications, including several in top-tier journals including Nature and Science. Olof received his PhD at the Karolinska Institute and is an associate professor in Experimental Medicine at the same university.
Chief Financial Officer (CFO)
Mats Jonasson has more than 30 years of experience working with entrepreneur-driven development companies. He has served as CFO in several organizations, especially in Sweden but also abroad. Mats has also worked as a consultant within accounting, auditing and tax matters. He has been co-founder and co-owner of several companies over the years. Mats has a degree in small business economy from the Gothenburg School of Business, Economics and Law.
Chief Business Officer (CBO)
Mats Lindskog joins Oblique Therapeutics as CBO- Chief Business Officer in Stockholm Office. In his role, Mats will be responsible for business development initiatives to secure overall company growth and to build and strengthen business relations with current and new partners.
Mats has extensive knowledge and experience in areas that will be pivotal in his role at Oblique: Business development, pharmaceutical sales, and antibody technology.
He holds a Master of Science in biotechnology and a PhD within Antibody-based proteomics, both from the Royal Institute of Technology (KTH) in Stockholm. Following his studies Mats worked at start-up biotech companies within antibody production and protein-protein interaction studies and within pharmaceutical Sales and Marketing, specifically within Oncology.
Mats has since then held various executive positions at pharma companies within Business Unit Leadership, Strategy & Operations, Business Excellence and Commercial Operations.
Clinical Pain Advisor
Prof. Karlsten is currently the Head of the Multidisciplinary Pain Centre and Rehabilitation Medicine at Uppsala University Hospital, Sweden. He has a broad experience in pain research and management, medical in-licensing, R&D and projects in clinical development. Previously, he has held positions such as Medical Science Director at AstraZeneca, Senior Consultant at Uppsala University Hospital, and has worked with KOL networks in Europe, the U.S. and Japan. His background of studies includes M.D. and a Ph.D. in Medical Science from Uppsala University, Sweden, and a diploma in Pharmaceutical Medicine from the Karolinska Institute in Stockholm, Sweden.
